BMS-Celgene Merger: Worth It?

BMS-Celgene Merger: Worth It?

In January, Bristol-Myers Squibb (BMS) announced that they would acquire Celgene at the price tag of approximately $74B with a 58.6% premium paid by BMS over Celgene’s share price at time of acquisition. We have analyzed the deal to answer the question: Was it worth it? Read more to find out!

Related Posts

February 12, 2019

BMS-Celgene Merger: Worth It?

Leave A Reply